Onkológia 5/2018
Androgen deprivation therapy and radiotherapy of prostate cancer
Radiotherapy remains one of standard options of local therapy of prostate cancer. Besides technology advances resulting in better quality of prostate irradiation, effectiveness of radiotherapy can be improved by androgen deprivation. Large volume of published evidence points to better results of radiotherapy when combined with short term or long term androgen deprivation therapy (ADT) in selected patients. Radiotherapy alone in low risk of treatment failure after local treatment group, combination with short term in intermediate risk and long term in high risk has been instablished in clinical practice. It appears that combination with ADT is not benefitial in all cases with intermediate risk disease and not for all patients in high risk group 2 - 3-year long term ADT is necessary. Thus, the risk of side effects of ADT can be reduced mainly by proper patient selection. After showing activity in metastatic setting, multiple therapies have been experimentally combined with radiotherapy and ADT in recent years but they have yet to change the standard of care.
Keywords: prostate cancer, androgen deprivation therapy, docetaxel
